Media Centre

Featured Media Release

14 May 2013 - GSK Australia Reports 2012 Results to ASIC

GlaxoSmithKline (GSK) reported to the Australian Securities and Investment Commission (ASIC) for 2012 sales of $1,452m and a total profit before tax of $41m.


Media Releases

Australian Crohn’s sufferers urged to take part in worldwide research into new treatment

Australians suffering from the debilitating bowel condition, Crohn’s disease (CD), are being invited to participate in a worldwide study to assess a potential new treatment which could alleviate symptoms and improve their quality of life.



GSK Patient Support Programs Statement

GSK Australia provides patient support programs as part of a commitment to the quality use of medicines only after they have been prescribed a particular medicine/s.



GSK Awarded Funds to Advance Dermal Treatment with Starpharma’s Dendrimers

GlaxoSmithKline (GSK), and Starpharma (ASX:SPL, OTCQX:SPHRY) today announced that GSK was awarded a grant to advance a dermal treatment based on Starpharma’s dendrimer drug delivery technology.



Worldwide study to help Australians breathe easier needs volunteers

Australian sufferers of chronic obstructive pulmonary disorder (COPD), one of the most important causes of breathlessness and difficulty performing tasks of normal daily life, have the opportunity to participate in a worldwide study, starting this...



PBS listing of new treatment for enlarged prostate

Australian men who suffer from the symptoms of an enlarged prostate – like frequent urination, waking at night to urinate; a sense of incomplete emptying after urination; straining to urinate or a feeling of extreme urgency to urinate1 - now have a...



GSK discloses payments to Australian healthcare professionals

As part of an ongoing commitment to increase transparency, GlaxoSmithKline Australia today disclosed the aggregate amount of fees paid to Australian healthcare professionals and health-related organisations for all sponsorships, grants, speaking...



GSK to disclose payments to healthcare professionals by June 2011

As part of an ongoing commitment to increase transparency, GlaxoSmithKline announced today the intention to publish, by June 2011, the total amount of fees paid to Australian healthcare professionals for speaking and consulting services during 2010.



GSK statement on AvodartTM (dutasteride) for prostate cancer risk reduction

GlaxoSmithKline (GSK) announced today that it will no longer pursue global approval (marketing authorisation) for the use of Avodart® (dutasteride) to reduce the risk of prostate cancer. The Company will withdraw applications from regulatory review...



Twice-yearly osteoporosis treatment Prolia® (denosumab) available on the PBS for postmenopausal women with osteoporosis1

Australian women with postmenopausal osteoporosis – a chronic bone disease that weakens bones and makes them more likely to fracture – now have access to another treatment option as Prolia® (denosumab) is made available on the Pharmaceutical...



Q. Puzzled about vaccination? A.

A new website,, has been launched to provide all Australians with simple, easy to understand information about vaccine-preventable diseases at the time of life when it is most relevant to them.


< 4 5 6 7 8 9 10 11 12 13 14 >